ArticlePloS one2024
Reinterpretation of the results of randomized clinical trials.
Article in PloS one, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Systematic Review on the Efficacy of Atenolol in Antihypertensive Treatment: Recommendation from the Brazilian Society of Cardiology.Arquivos brasileiros de cardiologia · 2025Pooled it
- TheJournal of Korean medical science · 2025Review
- On the effect of flexible adjustment of the p value significance threshold on the reproducibility of randomized clinical trials.PloS one · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRandomized clinical trials (RCTs) shape our clinical practice. Several studies report a mediocre replicability rate of the studied RCTs. Many researchers believe that the relatively low replication rate of RCTs is attributed to the high p value significance threshold. To solve this problem, some researchers proposed using a lower threshold, which is inevitably associated with a decrease in the study power.
methodsThe results of 22 500 RCTs retrieved from the Cochrane Database of Systematic Reviews (CDSR) were reinterpreted using 2 fixed p significance threshold (0.05 and 0.005), and a recently proposed flexible threshold that minimizes the weighted sum of errors in statistical inference.
resultsWith p < 0.05 criterion, 28.5% of RCTs were significant; p < 0.005, 14.2%; and p < flexible threshold, 9.9% (2/3 of significant RCTs based on p < 0.05 criterion, were found not significant). Lowering the p cut-off, although decreases the false-positive rate, is not generally associated with a lower weighted sum of errors; the false-negative rate increases (the study power decreases); important treatments may be left undiscovered. Accurate calculation of the optimal p value thresholds needs knowledge of the variance in each study arm, a posteriori.
conclusionsLowering the p value threshold, as it is proposed by some researchers, is not reasonable as it might be associated with an increase in false-negative rate. Using a flexible p significance threshold approach, although results in a minimum error in statistical inference, might not be good enough too because only a rough estimation may be calculated a priori; the data necessary for the precise computation of the most appropriate p significance threshold are only available a posteriori. Frequentist statistical framework has an inherent conflict. Alternative methods, say Bayesian methods, although not perfect, would be more appropriate for the data analysis of RCTs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.